Christopher D. Dupont
Title
Cited by
Cited by
Year
Immune response and immunopathology during toxoplasmosis
CD Dupont, DA Christian, CA Hunter
Seminars in immunopathology 34 (6), 793-813, 2012
2842012
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1
K Hirahara, K Ghoreschi, XP Yang, H Takahashi, A Laurence, G Vahedi, ...
Immunity 36 (6), 1017-1030, 2012
2392012
Parasite fate and involvement of infected cells in the induction of CD4+ and CD8+ T cell responses to Toxoplasma gondii
CD Dupont, DA Christian, EM Selleck, M Pepper, M Leney-Greene, ...
PLoS Pathog 10 (4), e1004047, 2014
782014
Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cells
ED Tait, KA Jordan, CD Dupont, TH Harris, B Gregg, EH Wilson, ...
The Journal of Immunology 185 (3), 1502-1512, 2010
572010
A host GPCR signaling network required for the cytolysis of infected cells facilitates release of apicomplexan parasites
MG Millholland, S Mishra, CD Dupont, MS Love, B Patel, D Shilling, ...
Cell host & microbe 13 (1), 15-28, 2013
362013
African trypanosomes contain 5-methylcytosine in nuclear DNA
KT Militello, P Wang, SK Jayakar, RL Pietrasik, CD Dupont, K Dodd, ...
Eukaryotic cell 7 (11), 2012-2016, 2008
342008
Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii
KA Jordan, CD Dupont, ED Tait, HC Liou, CA Hunter
International immunology 22 (11), 851-861, 2010
122010
Guanylate-binding proteins: niche recruiters for antimicrobial effectors
CD Dupont, CA Hunter
Immunity 37 (2), 191-193, 2012
112012
Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response
CD Dupont, IL Scully, RM Zimnisky, B Monian, CP Rossitto, EB O'Connell, ...
MSphere 3 (4), e00217-18, 2018
102018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody
RB Gombos, A Gonzalez, M Manrique, D Chand, D Savitsky, B Morin, ...
PLoS One 13 (4), e0191926, 2018
102018
Flt3 ligand is essential for survival and protective immune responses during toxoplasmosis
CD Dupont, GH Pritchard, S Hidano, DA Christian, S Wagage, G Muallem, ...
The Journal of Immunology 195 (9), 4369-4377, 2015
102015
Longitudinal multiparameter single-cell analysis of macaques immunized with pneumococcal protein-conjugated or unconjugated polysaccharide vaccines reveals distinct antigen …
B Jia, LK McNeil, CD Dupont, K Tsioris, RM Barry, IL Scully, AO Ogunniyi, ...
PloS one 12 (9), e0183738, 2017
92017
Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates
R Gombos, A Gonzalez, M Manrique, D Chand, D Savitsky, B Morin, ...
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5, 2017
32017
RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial
DR Camidge, SM Gadgeel, HJ Wilkins, G Weems, R Santana-Davila, ...
Annals of Oncology 29, viii417, 2018
22018
Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced …
C Drescher, KN Moore, JF Liu, DM O’Malley, EW Wang, JSZ Wang, ...
Annals of Oncology 29, viii412-viii413, 2018
22018
Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in patients with solid tumors
P De Souza, A Malczewski, I Proscurshim, G Yuan, E Coart, C Dupont, ...
CANCER RESEARCH 78 (13), 2018
22018
Abstract CT104: Evaluation of peripheral T cell subset proliferation as a pharmacodynamic assay to guide the development of anti-CTLA-4 and PD-1 antibody combinations in …
P De Souza, A Malczewski, I Proscurshim, G Yuan, E Coart, C Dupont, ...
Cancer Research 78 (13 Supplement), CT104-CT104, 2018
22018
Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation.
KN Moore, C Dresher, J Liu, DM O'Malley, EW Wang, JSZ Wang, ...
Journal of Clinical Oncology 36 (15_suppl), 3086-3086, 2018
22018
Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
BA Wilky, P Kumthekar, R Wesolowski, JJ Hwang, SI Park, I Proscurshim, ...
Journal of Clinical Oncology 36 (15_suppl), 3075-3075, 2018
22018
Phase I/II study of CTLA-4 inhibitor AGEN1884+ PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors
J Coward, C Lemech, T Meniawy, CD Dupont, AM Gonzalez, M Lim, ...
Annals of Oncology 29, viii417, 2018
12018
The system can't perform the operation now. Try again later.
Articles 1–20